Proteasome inhibitors as experimental therapeutics of autoimmune diseases

Current treatment strategies for rheumatoid arthritis (RA) consisting of disease-modifying anti-rheumatic drugs or biological agents are not always effective, hence driving the demand for new experimental therapeutics. The antiproliferative capacity of proteasome inhibitors (PIs) has received consid...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Arthritis research & therapy Ročník 17; číslo 1; s. 17
Hlavní autori:	Verbrugge, Sue Ellen, Scheper, Rik J, Lems, Willem F, de Gruijl, Tanja D, Jansen, Gerrit
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London BioMed Central 28.01.2015 BioMed Central Ltd
Predmet:	Antigen presenting cells Antigens Antirheumatic agents Arthritis, Rheumatoid - drug therapy Autoimmune Diseases - drug therapy Development and progression Drug therapy Health aspects Homeopathy Humans Interleukins Materia medica and therapeutics Medicine Medicine & Public Health Orthopedics Physiological aspects Proteasome Endopeptidase Complex - adverse effects Proteasome Inhibitors - therapeutic use Review Rheumatoid factor Rheumatology Systemic lupus erythematosus T cells Therapeutics Systemic Lupus Erythematosus Major Histocompatibility Complex Class Immune Effector Cell Bortezomib Rheumatoid Arthritis
ISSN:	1478-6354, 1478-6362, 1478-6354, 1478-6362
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!